Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development (DCED) Secretary Rick Siger cut the ribbon on SCHOTT Pharma USA’s newly improved and expanded manufacturing facility in Lebanon County. This expansion project helps retain more than 200 jobs, triples SCHOTT’s manufacturing capacity in the United States, and continues growing Pennsylvania’s robust life sciences industry.
Since 2003, SCHOTT’s Lebanon facility has specialized in drug containment solutions and delivery systems for injectable drugs, producing high‑quality core and specialty vials made from FIOLAX borosilicate glass, built to carry and protect life-saving cancer treatments while in transit.
Valued at nearly $50 billion, Pennsylvania’s life sciences sector is a national powerhouse, employing more than 100,000 people across nearly 3,100 companies and world-renowned research institutions throughout the Commonwealth. Over the past five years, Pennsylvania researchers and companies have secured over 10,700 new life sciences patents — the fourth-highest total in the country.
“SCHOTT Pharma’s expansion will boost our innovation economy and further strengthen the pharmaceutical manufacturing ecosystem here in Pennsylvania,” said DCED Secretary Rick Siger.
SCHOTT Pharma USA, the North American branch of Germany’s SCHOTT Pharma, is focused on specialty glass, glass-ceramics, and other advanced materials. In 2025, SCHOTT Pharma generated an estimated $1.1 billion in global revenue — with two manufacturing facilities in Lebanon and Duryea, supporting more than 350 jobs in Pennsylvania.
